Outcomes of Focal Ablation for Prostate Cancer
Recruiting · NCT05478694 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Texas Southwestern Medical Center
View the official record on ClinicalTrials.gov →What this trial is about
This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
Who can take part
Age range
18 Years to 90 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
- Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease
- Age 18-90 years.
- Life expectancy \> 1 year
- Ability to understand and the willingness to sign a written informed consent.
Exclusion criteria
- Anatomic abnormalities that do not allow for focal ablation
- Evidence of non-organ confined disease that is not feasible for ablation
- Has active urinary traction infection
Where it is running
1 location listed across 1 US state.
- UTSW - Dallas, Texas, United States